ARTICLE | Clinical News
United Neuroscience's vaccine leads to 96% response rate in Chinese Phase IIa for Alzheimer's
January 18, 2019 8:26 PM UTC
United Neuroscience Inc. (Dublin, Ireland) said UB-311 led to a 96% response rate and met the primary endpoints of safety and immunogenicity in a Phase IIa trial to treat mild Alzheimer's disease. Immunogenicity was determined by measuring change from baseline in anti-β amyloid antibody titers.
Data will be presented in March at the International Conference on Alzheimer's and Parkinson's Diseases in Lisbon and published in peer-reviewed medical journals...
BCIQ Target Profiles